W
William F. Mieler
Researcher at University of Illinois at Chicago
Publications - 193
Citations - 6897
William F. Mieler is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Visual acuity & Retinal detachment. The author has an hindex of 40, co-authored 185 publications receiving 6144 citations. Previous affiliations of William F. Mieler include University of Chicago & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
TL;DR: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.
Journal ArticleDOI
Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy
TL;DR: Patients should be aware of the risk of toxicity and the rationale for screening (to detect early changes and minimize visual loss, not necessarily to prevent it), and the drugs should be stopped if possible when toxicity is recognized or strongly suspected.
Journal ArticleDOI
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology
Journal ArticleDOI
Spectral-Domain Optical Coherence Tomography: A Comparison of Modern High-Resolution Retinal Imaging Systems
TL;DR: Advances in high-resolution imaging of the anterior and posterior segment have revealed new in vivo details of anatomic, physiologic, and pathologic data for the practice of ophthalmology, and as the technology develops, SD OCT will continue to provide new insights about ocular structure and disease.
Journal ArticleDOI
Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Seenu M. Hariprasad,Gaurav K. Shah,William F. Mieler,Leonard Feiner,Kevin J. Blinder,Nancy M. Holekamp,H. Gao,Randall A. Prince +7 more
TL;DR: Orally administered gatifloxacin achieves therapeutic levels in the noninflamed human eye, and the activity spectrum appropriately encompass the bacterial species most frequently involved in the various causes of endophthalmitis.